Eilmeldung

RUVenezuela Hit by Strongest Earthquake Since 1900 INTLMicron Soars on Blockbuster Earnings Driven by AI Demand AUBrisbane Lions Dominate Sydney Swans in AFL Thursday Match at Gabba INTLAirport Ceiling Collapses as Double Earthquake Strikes Venezuela USTexas Considers Mandating Bible Stories in Public Schools KRHalf of Stranded South Korean Vessels Exit Strait of Hormuz INTLAmazon to Invest Additional $13 Billion in India's AI and Cloud Infrastructure UKScouts Introduce New Badges Focused on Digital Skills and Online Safety INMK Stalin reacts to TN CM Vijay's assembly speech taunting Udhayanidhi Stalin INTLDangerous Heat Stress Affects a Billion More People Globally Since 1970s RUVenezuela Hit by Strongest Earthquake Since 1900 INTLMicron Soars on Blockbuster Earnings Driven by AI Demand AUBrisbane Lions Dominate Sydney Swans in AFL Thursday Match at Gabba INTLAirport Ceiling Collapses as Double Earthquake Strikes Venezuela USTexas Considers Mandating Bible Stories in Public Schools KRHalf of Stranded South Korean Vessels Exit Strait of Hormuz INTLAmazon to Invest Additional $13 Billion in India's AI and Cloud Infrastructure UKScouts Introduce New Badges Focused on Digital Skills and Online Safety INMK Stalin reacts to TN CM Vijay's assembly speech taunting Udhayanidhi Stalin INTLDangerous Heat Stress Affects a Billion More People Globally Since 1970s

investment restrictions

Stabil2 Meldungen2 QuellenZuletzt aktualisiert: 4 g önce

Verwandte ThemenChina United States investment pharmaceuticals biotech technology transfer innovation biotechnology

Neueste Meldungen

US-China Biotech Deals Face Complications Amid Investment Restrictions

Business·4 g önceKI-Zusammenfassung

US-China Biotech Deals Face Complications Amid Investment Restrictions

Cross-border biotech deals between China and the US are facing increased complexity and potential slowdown due to US restrictions on investment and technology transfers, according to analysts. Despite challenges, innovation from China is expected to drive continued partnerships, with out-licensing agreements projected to reach $240 billion.

Chinese Biotech Firms Eye Global Markets Amid US Regulatory Hurdles

11.06.2026KI-Zusammenfassung

Chinese Biotech Firms Eye Global Markets Amid US Regulatory Hurdles

Chinese biotech companies are pursuing global commercialization despite US regulatory barriers, leveraging cost advantages in markets like Europe. Insilico Medicine's Ren Feng highlighted the need for internationalization and the challenge of lacking overseas clinical teams, suggesting business development deals as a solution.